Carmat (ALCAR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Carmat (ALCAR) has a cash flow conversion efficiency ratio of 0.344x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-17.58 Million ≈ $-20.56 Million USD) by net assets (€-51.13 Million ≈ $-59.78 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Carmat - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Carmat's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Carmat (ALCAR) total liabilities for a breakdown of total debt and financial obligations.
Carmat Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Carmat ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Orcoda Ltd
AU:ODA
|
-0.059x |
|
Reach Resources Ltd
AU:RR1
|
-0.032x |
|
Tenon Medical Inc
NASDAQ:TNON
|
-0.797x |
|
Gayatri Highways Limited
NSE:GAYAHWS
|
1.168x |
|
CaliberCos Inc. Class A Common Stock
NASDAQ:CWD
|
-0.497x |
|
Zelan Bhd
KLSE:2283
|
-0.271x |
|
Evolution Energy Minerals Ltd
AU:EV1
|
-0.274x |
|
Solis Minerals Ltd
V:SLMN
|
-0.043x |
Annual Cash Flow Conversion Efficiency for Carmat (2010–2024)
The table below shows the annual cash flow conversion efficiency of Carmat from 2010 to 2024. For the full company profile with market capitalisation and key ratios, see Carmat (ALCAR) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-51.13 Million ≈ $-59.78 Million |
€-43.31 Million ≈ $-50.64 Million |
0.847x | -30.68% |
| 2023-12-31 | €-43.76 Million ≈ $-51.16 Million |
€-53.48 Million ≈ $-62.52 Million |
1.222x | +104.05% |
| 2022-12-31 | €1.80 Million ≈ $2.11 Million |
€-54.38 Million ≈ $-63.57 Million |
-30.175x | -788.21% |
| 2021-12-31 | €-13.72 Million ≈ $-16.04 Million |
€-60.17 Million ≈ $-70.34 Million |
4.385x | +179.66% |
| 2020-12-31 | €7.82 Million ≈ $9.14 Million |
€-43.03 Million ≈ $-50.31 Million |
-5.504x | -232.89% |
| 2019-12-31 | €24.34 Million ≈ $28.46 Million |
€-40.24 Million ≈ $-47.05 Million |
-1.653x | +11.04% |
| 2018-12-31 | €20.54 Million ≈ $24.01 Million |
€-38.17 Million ≈ $-44.63 Million |
-1.859x | -337.96% |
| 2017-12-31 | €57.21 Million ≈ $66.88 Million |
€-24.28 Million ≈ $-28.38 Million |
-0.424x | +42.37% |
| 2016-12-31 | €28.89 Million ≈ $33.77 Million |
€-21.27 Million ≈ $-24.87 Million |
-0.736x | +93.99% |
| 2015-12-31 | €1.40 Million ≈ $1.64 Million |
€-17.19 Million ≈ $-20.09 Million |
-12.248x | -407.32% |
| 2014-12-31 | €7.76 Million ≈ $9.08 Million |
€-18.75 Million ≈ $-21.92 Million |
-2.414x | -81.08% |
| 2013-12-31 | €7.23 Million ≈ $8.45 Million |
€-9.64 Million ≈ $-11.27 Million |
-1.333x | +26.17% |
| 2012-12-31 | €9.94 Million ≈ $11.62 Million |
€-17.95 Million ≈ $-20.99 Million |
-1.806x | -400.34% |
| 2011-12-31 | €26.89 Million ≈ $31.44 Million |
€-9.71 Million ≈ $-11.35 Million |
-0.361x | +19.55% |
| 2010-12-31 | €15.49 Million ≈ $18.11 Million |
€-6.95 Million ≈ $-8.13 Million |
-0.449x | -- |
About Carmat
Carmat SA designs and develops total artificial heart for patients with advanced heart failure in France and internationally. The company offers Aeson, an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The company was incorporated in 2008 and is headquartered in Vélizy-Villacoublay, France.